Bioanalytical Testing Services Market Report 2026

The bioanalytical testing services market size has grown rapidly in recent years. It will grow from $3.73 billion in 2025 to $4.11 billion in 2026 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to growth in pharmaceutical r&d activities, rising demand for clinical drug testing support, increasing reliance on contract testing organizations, expansion of regulatory compliance needs, early development of analytical technology infrastructure.

The bioanalytical testing services market size is expected to see rapid growth in the next few years. It will grow to $6.27 billion in 2030 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to rising biologics and biosimilar development, increasing clinical trial intensity worldwide, growing focus on precise pharmacokinetic assessment, expansion of personalized medicine initiatives, stronger emphasis on safe therapeutic validation. Major trends in the forecast period include increasing demand for drug assessment accuracy, rising focus on reliable quantification of analytes, growing expansion of outsourced bioanalytical testing, strengthening emphasis on regulatory standard compliance, increasing adoption of specialized biological sample analysis.

The rising government initiative to control infectious disease outbreaks is significantly contributing to the growth of the bioanalytical testing services market. The outbreak of the COVID-19 pandemic has aided in the growth in demand for bioanalytical testing services. Countries worldwide have been taking initiatives and increasing spending to prevent the spread and impact of the diseases. For instance, in March 2023, according to a report published by the Congressional Research Service, a US-based public policy research institute. The funding from National Institutes of Health (NIH) for Allergy/Infectious Diseases (NIAID) has increased from $6.32 billion to $6,562 in 2023. Therefore, the rising government initiatives to control infectious disease outbreaks is driving the bioanalytical testing services market.

Major companies operating in the bioanalytical testing services market are focused on introducing advanced solutions, such as reverse transcription PCR (RT-PCR) tests, to sustain their position in the market. The reverse transcription PCR (RT-PCR) test is a laboratory technique that involves the conversion of RNA into complementary DNA (cDNA) using an enzyme called reverse transcriptase. For instance, in June 2023, Eurofins Scientific SE, a France-based testing laboratory company, launched the NovaType SARS-CoV-2 RT-PCR assay. The NovaType SARS-CoV-2 RT-PCR assay is clinically validated and has a short turnaround time, which is suitable for re-testing millions of positive samples to detect if the virus is a specific variant. It is a real-time reverse transcription PCR (RT-PCR) test designed for the qualitative detection of SARS-CoV-2, the virus that causes COVID-19, and the subsequent identification of specific variants, such as B.1.1.7 and B.1.351.

In August 2023, Scantox AB, a Denmark-based provider of bioanalytical and toxicology services, acquired Q&Q Labs AB for an undisclosed sum. Through this acquisition, Scantox AB seeks to enhance its bioanalytical service portfolio and broaden its capabilities in supporting drug development and safety evaluation. Q&Q Labs AB is a Sweden-based company that offers bioanalytical testing services, including pharmacokinetic, immunogenicity, and biomarker analyses for pharmaceutical and biotechnology firms.

Major companies operating in the bioanalytical testing services market report are CD BioSciences, Thermo Fisher Scientific Inc., Merck KGaA, Laboratory Corporation of America Holdings (LabCorp), Eurofins Scientific SE, ICON plc, PPD Inc., SGS SA, WuXi AppTec, Syneos Health Inc., Charles River Laboratories Inc., Intertek Group, Covance Inc., PAREXEL International Corporation, Medpace Holdings Inc., Almac Group, Pace Analytical Services LLC, Altasciences, BioAgilytix Labs, Frontage Laboratories Inc., Toxikon Inc., Absorption Systems LLC, Lotus Labs Pvt. Ltd., Bioneeds India Private Limited, Vipragen Biosciences Pvt. Ltd., Source BioScience.

North America was the largest region in the bioanalytical testing services market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bioanalytical testing services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bioanalytical testing services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The bioanalytical testing services market includes revenues earned by entities by providing services such as method development, high throughput sample analysis, method validation, and pharmacokinetic and toxicokinetic support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.